Mavacamten

玛伐凯泰

Report date: 2026/04/07 18:01:53
NMEFirst In Class

Base Information

Drug NameMavacamten
Drug Alias NameMAVAMAVA(Myokardia)Camzyos迈凡妥®SAR-439152 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCardiac myosin inhibitorsProtein allosteric inhibitors
TargetsCardiac myosin
Therapy Area/IndicationsVentricular Outflow ObstructionHeart Failure, DiastolicCardiomyopathy, Hypertrophic
Global Approved IndicationsCardiomyopathy, Hypertrophic
Approved Indications in ChinaCardiomyopathy, Hypertrophic
Original Approved Country/TerritoryUnited States
Original Approved Date2022/04/28
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMyokardia IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanySanofiBristol-Myers Squibb Pharma Eeig +[4] 
Inactive CompaniesMyokardia IncBristol-Myers Squibb Australia Pty LtdLian Cardiovascular Ltd +[5] 
Active IndicationsHeart Failure, DiastolicCardiomyopathy, Hypertrophic
Inactive IndicationsVentricular Outflow Obstruction

Other Information

ATC CodeN/A
Related LinksN/A